Patents by Inventor Daniel La

Daniel La has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110118250
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: October 21, 2010
    Publication date: May 19, 2011
    Applicant: Amgen Inc.
    Inventors: Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Wenge Zhong
  • Publication number: 20110118252
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: November 12, 2010
    Publication date: May 19, 2011
    Applicant: Amgen Inc.
    Inventors: Tae-Seong Kim, David Bauer, Steven Bellon, Alessandro Boezio, Shon Booker, Deborah Choquette, Derin C. D'Amico, Noel D'Angelo, Celia Dominguez, Ingrid M. Fellows, Julie Germain, Russell Graceffa, Jean-Christophe Harmange, Satoko Hirai, Daniel La, Matthew Lee, Longbin Liu, Mark H. Norman, Michele Potashman, Philip Roveto, Aaron C. Siegmund, Ning Xi, Kevin Yang
  • Patent number: 7872009
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: January 18, 2011
    Assignee: Amgen Inc.
    Inventors: Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Wenge Zhong
  • Publication number: 20100317668
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
    Type: Application
    Filed: August 20, 2010
    Publication date: December 16, 2010
    Applicant: Amgen Inc.
    Inventors: Russell GRACEFFA, Matthew KALLER, Daniel LA, Patricia LOPEZ, Vinod F. PATEL, Wenge ZHONG
  • Patent number: 7838676
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, W, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: November 23, 2010
    Assignee: Amgen Inc.
    Inventors: Qiufen Xue, Brian K. Albrecht, Denise Lyn Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Bryant Yang, Wenge Zhong
  • Patent number: 7803809
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: September 28, 2010
    Assignee: Amgen Inc.
    Inventors: Russell Graceffa, Matthew Kaller, Daniel La, Patricia Lopez, Vinod F. Patel, Wenge Zhong
  • Publication number: 20100222338
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: May 13, 2010
    Publication date: September 2, 2010
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian K. Albrecht, Michael D. Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Daniel Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig E. Masse, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang, Holger Monenschein, Thomas Nguyen
  • Patent number: 7745484
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: June 29, 2010
    Assignee: Amgen Inc.
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian K. Albrecht, Michael D. Bartberger, James Brown, Ryan Brown, Stuart C. Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Dan Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod F. Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang
  • Publication number: 20100120774
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
    Type: Application
    Filed: November 12, 2008
    Publication date: May 13, 2010
    Applicant: Amgen Inc.
    Inventors: Russell Graceffa, Matthew Kaller, Daniel La, Patricia Lopez, Vinod F. Patel, Wenge Zhong
  • Publication number: 20100087429
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: September 11, 2009
    Publication date: April 8, 2010
    Applicant: Amgen Inc.
    Inventors: Ryan White, Albert Amegadzie, Marian C. Bryan, Jian Jeffrey Chen, Alan C. Cheng, Thomas Dineen, Oleg Epstein, Vijay Keshav Gore, Zihao Hua, Jason Brooks Human, Hongbing Huang, Charles Kreiman, Daniel La, Qingyian Liu, Vu Van Ma, Isaac Marx, Vinod F. Patel, Wenyuan Qian, Matthew Weiss, Chester Chenguang Yuan
  • Publication number: 20090181123
    Abstract: The present invention relates generally to methods and compositions for enhancing the flavor or other properties of wine, and wine products produced by such methods.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 16, 2009
    Inventor: Daniel La Caze
  • Publication number: 20090176774
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: June 9, 2008
    Publication date: July 9, 2009
    Applicant: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, David C. McGowan, Douglas A. Whittington, Gregory J. Habgood, Vinod F. Patel, Daniel La
  • Publication number: 20080312232
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: April 26, 2006
    Publication date: December 18, 2008
    Applicant: Amgen Inc.
    Inventors: Tae-Seong Kim, David Bauer, Steven Bellon, Alessandro Boezio, Shon Booker, Deborah Choquette, Derin C. D'Amico, Noel D'Angelo, Celia Dominguez, Ingrid M. Fellows, Julie Germain, Russell Graceffa, Jean-Christophe Harmange, Satoko Hirai, Daniel La, Matthew Lee, Longbin Liu, Mark H. Norman, Michele Potashman, Philip Roveto, Aaron C. Siegmund, Ning Xi, Kevin Yang
  • Patent number: 7435823
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 24, 2005
    Date of Patent: October 14, 2008
    Assignee: Amgen Inc.
    Inventors: Michele Potashman, Tae-Seong Kim, Steven Bellon, Shon Booker, Yuan Cheng, Joseph L. Kim, Andrew Tasker, Ning Xi, Shimin Xu, Jean-Christophe Harmange, George Borg, Matthew Weiss, Brian L. Hodous, Russell Graceffa, William H. Buckner, Craig E. Masse, Deborah Choquette, Matthew W. Martin, Julie Germain, Lucian V. DiPietro, Stuart C. Chaffee, Joseph J. Nunes, John L. Buchanan, Gregory J. Habgood, David C. McGowan, Douglas A. Whittington, Daniel La, Vinod F. Patel
  • Publication number: 20070185144
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, W, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: November 10, 2006
    Publication date: August 9, 2007
    Applicant: Amgen Inc.
    Inventors: Wenge Zhong, Stephen Hitchcock, Brian Albrecht, Michael Bartberger, James Brown, Ryan Brown, Stuart Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Dean Hickman, Daniel Horne, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod Patel, Lewis Pennington, Matthew Weiss, Qiufen Xue, Bryant Yang
  • Publication number: 20070185103
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: November 14, 2006
    Publication date: August 9, 2007
    Inventors: Brian Albrecht, Denise Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod Patel, Lewis Pennington, Matthew Weiss, Quifen Xue, Bryant Yang, Wenge Zhong
  • Publication number: 20070185171
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Application
    Filed: October 20, 2006
    Publication date: August 9, 2007
    Inventors: Julie Germain, Benny Askew, David Bauer, Deborah Choquette, Lucian Dipietro, Russell Graceffa, Jean-Christophe Harmange, Qi Huang, Joseph Kim, Daniel La, Aiwen Li, Nobuko Nishimura, Rana Nomak, Vinod Patel, Michele Potashman, Babak Riahi, Thomas Storz, Simon Van Der Plas, Kevin Yang, Chester Yuan
  • Publication number: 20070173521
    Abstract: The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, W, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
    Type: Application
    Filed: November 14, 2006
    Publication date: July 26, 2007
    Inventors: Qiufen Xue, Brian Albrecht, Denise Andersen, Michael Bartberger, James Brown, Ryan Brown, Stuart Chaffee, Yuan Cheng, Michael Croghan, Russell Graceffa, Scott Harried, Stephen Hitchcock, Randall Hungate, Ted Judd, Matthew Kaller, Charles Kreiman, Daniel La, Patricia Lopez, Craig Masse, Holger Monenschein, Thomas Nguyen, Thomas Nixey, Vinod Patel, Lewis Pennington, Matthew Weiss, Bryant Yang, Wenge Zhong
  • Patent number: 6556463
    Abstract: A discharge lamp for a motor vehicle headlight is fed through a power supply device which includes a dc/ac converter. The power supplied to the dc/ac converter is modulated over time, preferably in a pseudo-random sequence. A power supply device adapted to perform this method is also described.
    Type: Grant
    Filed: September 27, 2000
    Date of Patent: April 29, 2003
    Assignee: Valeo Vision
    Inventors: Daniel La Dret, Jean-Marc Nicolaï
  • Patent number: 5220944
    Abstract: A dual blend door for a motor vehicle climate control system allows operation of the door within an air passage with lesser effort and thus may be operated by a smaller and more efficient mechanism. The dual blend door provides a main door within which is an opening covered by a smaller inner door. Both the main door and the inner door are coaxially mounted on the same pivot shaft and pivoting of the shaft first opens the inner door, relieving the air pressure exerted upon the main door. Continued pivoting of the pivot shaft beyond a predetermined angle engages drive means comprising cooperating elements of the inner door and main door to open the main door subsequent to the opening of the inner door. In broader applications, the invention constitutes a fluid passage door assembly for controlling the flow of fluid through a passage.
    Type: Grant
    Filed: July 14, 1992
    Date of Patent: June 22, 1993
    Assignee: Ford Motor Company
    Inventors: Leslie Burnett, Daniel A. La Palm, Anthony J. Pastoria